


Product Details

Product name:	Anti-CD3 & GD2 (Nivatrotamab Biosimilar)	SKU:	BIO1001SM
Target Name:	CD3 & GD2	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	P07766 & NA	Concentration:	Lyophilized
Clone#:	Nivatrotamab (Bispecific)	Isotype:	IgG-ScFv
Reactivity:	Human	Calculated M.W.:	200.96 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH ₂ O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC




The purity of Anti-CD3 & GD2 Reference Antibody (Nivatrotamab) is 100.00% , determined by SEC-HPLC.

Bioactivity: FACS



Nivatrotamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to huCD3e-jurkat cells, and the EC50 was 3.481 nM.


Bioactivity: FACS



Nivatrotamab bound to huGD2-293 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Nivatrotamab bound to huGD2-293 cells, and the EC50 was 68.100 nM.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Function: Luciferase



Co-incubation of Nivatrotamab with Jurkat cells, then with the addition of hu GD2-his-293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Nivatrotamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.979 nM.